AbbVie Inc. (ABBV) Retained Earnings
The retained earnings for AbbVie Inc. (ABBV) is $-15.49 Billion with a year-over-year change of -96.11%. Retained earnings represent the cumulative net income that has been kept by the company rather than distributed to shareholders as dividends. It's a key component of shareholders' equity.
ABBV Retained Earnings Chart
Current Retained Earnings
$-15.49B
$-15.49 Billion
Year-over-Year Change
-96.11%
vs. $-7.90B prior year
Historical Data
16
Years of data available
Annual Retained Earnings History
| Year | Retained Earnings | YoY Change | % Change |
|---|---|---|---|
| 2025 | $-15.49B | $-7.59B | -96.11% |
| 2024 | $-7.90B | $-6.90B | -690.00% |
| 2023 | $-1.00B | $-5.78B | -120.90% |
| 2022 | $4.78B | +$1.66B | +52.99% |
| 2021 | $3.13B | +$2.07B | +196.40% |
| 2020 | $1.05B | $-3.66B | -77.63% |
| 2019 | $4.72B | +$1.35B | +40.05% |
| 2018 | $3.37B | $-2.09B | -38.30% |
| 2017 | $5.46B | +$1.08B | +24.69% |
| 2016 | $4.38B | +$2.13B | +94.75% |
| 2015 | $2.25B | +$1.71B | +320.19% |
| 2014 | $535.00M | $-1.03B | -65.86% |
| 2013 | $1.57B | +$1.57B | — |
| 2012 | $0 | +$0 | — |
| 2011 | $0 | +$0 | — |
| 2010 | $0 | — | — |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael